Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

OBJECTIVE: In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary endpoint) in the intent-to-treat (ITT) population....

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Gynecol Oncol
Главные авторы: González Martín, Antonio, Oza, Amit M., Embleton, Andrew C., Pfisterer, Jacobus, Ledermann, Jonathan A., Pujade-Lauraine, Eric, Kristensen, Gunnar, Bertrand, Monique A., Beale, Philip, Cervantes, Andrés, Kent, Emma, Kaplan, Richard S., Parmar, Mahesh K.B., Scotto, Nana, Perren, Timothy J.
Формат: Artigo
Язык:Inglês
Опубликовано: Academic Press 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6338677/
https://ncbi.nlm.nih.gov/pubmed/30449719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.08.036
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы